[A26-07] Avacopan (granulomatosis with polyangiitis or microscopic polyangiitis) – Addendum to Project A25-114
Last updated 05.03.2026
Project no.:
A26-07
Commission:
Commission awarded on 27.01.2026 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Muscles, bones and joints
Indication:
Adults with severe, active granulomatosis with polyangiitis or microscopic polyangiitis
Result of dossier assessment:
Unchanged after addendum: added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
DOI:
https://doi.org/10.60584/A26-07
| Project no. | Title | Status |
|---|---|---|
| A25-114 | Avacopan (granulomatosis with polyangiitis or microscopic polyangiitis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
05-03-2026 A G-BA decision was published.
G-BA documents on this decision